Differential expression of interleukin-1/Toll-like receptor signaling regulators in microscopic and ulcerative colitis

Figure 1 Relative gene and microRNA expressions in collagenous colitis patients, lymphocytic colitis patients, collagenous colitis patients with clinically active disease but histopathologically in remission, and lymphocytic colitis patients with clinically active disease but histopathologically in remission, ulcerative colitis patients, and ulcerative colitis patients in remission compared to controls. A: Relative interleukin-1receptor-associated kinase M (IRAK-M) gene expression; B: Relative microRNA-146a (miR-146a) expression; C: Relative microRNA-155 (miR-155) expression; D: Relative microRNA-21 (miR-21) expression; E: Relative interleukin-37 (IL-37) expression. miR: microRNA; CC: Collagenous colitis; CC-HR: CC patients with clinically active disease but histopathologically in remission; LC-HR: LC patients with clinically active disease but histopathologically in remission; UC: Ulcerative colitis; UC-R: UC patients in remission. Patients on budesonide treatment are indicated by circled symbols. The medians of the values are depicted lines and statistical outliers are marked as crosses (X).

Figure 2 Summary of the results. miR: microRNA; CC: Collagenous colitis; CC-HR: Collagenous colitis patients with clinically active disease but histopathologically in remission; LC: Lymphocytic colitis; LC-HR: LC patients with clinically active disease but histopathologically in remission; UC: Ulcerative colitis; UC-R: UC patients in remission; IRAK: Interleukin-1 receptor-associated kinase; TLR: Toll-like receptor; NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells; TRAF: Tumor necrosis factor receptor-associated factor.